Redmile Group, LLC
LARKSPUR, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$1.37B2026 Q3
Positions44
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.71.6%
What Changed This Quarter?
Top Holdings
NRIX
Nurix Therapeutics
13.7%
KRYS
Krystal Biotech
12.8%
SRRK
Scholar Rock
10.7%
STOK
Stoke Therapeutics
7.4%
IMNM
Immunome
6.9%
ABSI
Absci
5.3%
ETRA
Electra Therapeutics
4.5%
ANNX
Annexon
4.4%
New / Increased
6 new · 7 increased
ETRANEW
Electra Therapeutics
4.5%
ATTONEW
Attovia Therapeutics
1.5%
ADRXNEW
Adarx Pharmaceuticals
1.1%
OBXNEW
Obsidian Therapeutics
0.8%
Tcgx Acquisit…NEW
TCGX Acquisition
0.3%
NRIX
Nurix Therapeutics
13.7%
+93.9%
ANNX
Annexon
4.4%
+20.3%
RGNX
Regenxbio
2.8%
+15.6%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.